We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: minimal residual disease
MedXY News
EnglishTag

minimal residual disease

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Refining Risk Stratification in Newly Diagnosed Multiple Myeloma: Circulating Tumor Cells Identify a Disseminated Genomic High-Risk Phenotype Within IMS-IMWG 2025 Staging
Hematology-Oncologymultiple myelomagenomic risk stratification

Refining Risk Stratification in Newly Diagnosed Multiple Myeloma: Circulating Tumor Cells Identify a Disseminated Genomic High-Risk Phenotype Within IMS-IMWG 2025 Staging

By MedXY|Sep 12, 2026

Circulating tumor cells (CTCs) enhance the IMS-IMWG 2025 genomic staging by identifying a disseminated high-risk phenotype in newly diagnosed multiple myeloma, improving prognostic stratification and enabling minimally invasive disease moni

Early ctDNA MRD After Two Cycles Identifies Distinct Relapse Risk Groups in Advanced Hodgkin Lymphoma
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Hematology-Oncology
ctDNA
Hodgkin lymphoma

Early ctDNA MRD After Two Cycles Identifies Distinct Relapse Risk Groups in Advanced Hodgkin Lymphoma

By MedXY|May 14, 2026

In the GHSG HD21 trial, a validated ctDNA assay showed that MRD positivity after two treatment cycles strongly predicted inferior progression-free survival and improved early risk stratification, especially when combined with interim PET.

Circulating Tumor Cells as Prognostic Biomarkers in Transplant-Eligible Multiple Myeloma Patients Undergoing Frontline Quadruplet Therapy
Hematology-Oncologycirculating tumor cellsdaratumumab

Circulating Tumor Cells as Prognostic Biomarkers in Transplant-Eligible Multiple Myeloma Patients Undergoing Frontline Quadruplet Therapy

By MedXY|Oct 14, 2025

Circulating tumor cells (CTCs) serve as an independent prognostic biomarker in transplant-eligible newly diagnosed multiple myeloma patients treated with daratumumab-based quadruplet therapy, predicting progression-free survival and minimal

Ultrasensitive Circulating Tumor DNA as a Superior Biomarker for Remission Assessment in Large B-cell Lymphoma
Clinical Updatescirculating tumor DNALarge B-Cell Lymphoma

Ultrasensitive Circulating Tumor DNA as a Superior Biomarker for Remission Assessment in Large B-cell Lymphoma

By MedXY|Oct 7, 2025

Detection of circulating tumor DNA (ctDNA) provides a highly prognostic method for assessing remission in large B-cell lymphoma, outperforming conventional imaging and promising improved patient outcomes.

Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA
Clinical Updatesdaratumumabminimal residual disease

Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA

By MedXY|Oct 1, 2025

Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities